GILEAD SCIENCES, INC. is 109.0x more valuable than Vir Biotechnology, Inc. by market capitalization ($151.05 B vs $1.39 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | VIR | GILD |
|---|---|---|
| Market cap | $1.39 B | $151.05 B |
| US-listed rank | #2396 | #99 |
| Revenue (latest FY) | $68.56M | $29.44B |
| Net income (latest FY) | -$437.99M | $8.51B |
| Net margin | -638.9% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 762 | 981 |
GILEAD SCIENCES, INC. is 109.0x more valuable than Vir Biotechnology, Inc. by market capitalization ($151.05 B vs $1.39 B).
In their latest fiscal years, Vir Biotechnology, Inc. reported $68.56M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Vir Biotechnology, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.